Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Achillion to Present at Two Upcoming Investor Conferences

AAQL

NEW HAVEN, Conn., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at two upcoming investor conferences:

  • 2014 Deutsche Bank BioFEST on Monday, December 1, 2014 at 9:15 a.m. ET at the Four Seasons Hotel in Boston, MA; and
        
  • Piper Jaffray 26th Annual Healthcare Conference on Wednesday, December 3, 2014 at 11:30 a.m. ET at The New York Palace in New York, NY. 

The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion is seeking to apply its expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving patients' lives. The company's scientific excellence, integrated capabilities and experienced team position it to successfully achieve its goal of advancing new products along the entire continuum from the bench to the patient. Achillion's pipeline is currently focused on small molecule therapeutics for infectious disease and complement-related diseases. www.achillion.com

CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 752-5510
         gschulman@achillion.com
         
         Investors:
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         mfenton@achillion.com

Achillion Pharmaceuticals logo